Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts

Molecular Cancer Therapeutics

Volumn 5, Issue 4, 2006, Pages 919-926

  Leonetti, Carlo ^a   Scarsella, Marco ^a   Zupi, Gabriella ^a   Zoli, Wainer ^b   Amadori, Dino ^d   Medri, Laura ^b   Fabbri, Francesco ^b   Rosetti, Marco ^c   Ulivi, Paola ^c   Cecconetto, Lorenzo ^b   Bolla, Manlio ^e   Tesei, Anna ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^d DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^e NicOx SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (ACETYLOXY)BENZOIC ACID 4 (NITROOXY METHYL)PHENYL ESTER; CYTOTOXIC AGENT; FLUOROURACIL; NCX 4040; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; SULFORHODAMINE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL SURVIVAL; COLON CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ASPIRIN; CELL SURVIVAL; COLONIC NEOPLASMS; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; MALE; MICE; MICE, NUDE; NITRIC OXIDE; NITRO COMPOUNDS; ORGANOPLATINUM COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33646575901     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0536     Document Type: Article

References (46)

1. Ferlay J, Bray F, Pisani P, Parkin MD. GLOBOCAN 2000 - cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer-Base no. 5. Lyon (France): IARC Press; 2001.
2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-87.
3. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7: 1407-18.
4. Petrelli N, Douglass HO, Jr., Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7:1419-26.
5. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992;10:896-903.
6. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000;321:531-5.
7. The Meta-Analysis Group in Cancer. Modulation of fluorouracil by teucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766-75.
8. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:1559-65.
9. O' Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989;63:S1026-30.
10. O'Dwyer PJ, Manola J, Valone FH, et al. Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-L-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule - an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol 2001;19:2413-21.
11. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
12. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial fo oxaliplatin added to chronomodulated fluorouracil as first line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
13. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
14. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
15. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999;17:3553-9.
16. Huang Y, Horvath CM, Waxman S. Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon γ, indomethacin, and phenylbutyrate. Cancer Res 2000;60:3200-6.
17. Matsunaga N, Yamada N, Ohira M, et al. Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer. Oncol Rep 2004;11:167-71.
18. Chen WS, Liu JH, Liu JM, Lin JK. Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil- induced cytotoxicity of colon cancer cells. Anticancer Drugs 2004;15:287-94.
19. Ashktorab H, Dawkins FW, Mohamed R, Larbi D, Smoot DT. Apoptosis induced by aspirin and 5-fluoruracil in human colonic adenocarcinoma cells. Dig Dis Sci 2005;50:1025-32.
20. Trifan OC, Durham WF, Salazar VS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002;62:5778-84.
21. Yao M, Kargman S, Lam EC, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003;63:586-92.
22. Yao M, Zhou W, Sangha S, et al. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 2005;11:1618-28.
23. Lin J, Hsiao PW, Chiu TH, Chao JL. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol 2005;70:658-67.
24. Blanke CD, Mattek NC, Deloughery TG, Koop DR. A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer. Prostaglandins Other Lipid Mediat 2005;75:169-72.
25. Dy GK, Mandrekar S, Peethambaram PP, et al. A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer. Cancer Chemother Pharmacol 2005;56:623-8.
26. Pan CX, Loehrer P, Seitz D, et al. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first line therapy for advanced colorectal cancer. Oncology 2005;69: 63-70.
27. Williams JL, Borgo S, Hasan I, Castillo E, Traganos F, Rigas B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res 2001;61:3285-9.
28. Tesei A, Ulivi P, Fabbri F, et al. In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. J Transl Med 2005;3:7.
29. Rao CV. Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 2004;555:107-19.
30. Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, Rigas B. No-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+))mice. Biochem Biophys Res Commun 2004;313:784-8.
31. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003;124:600-7.
32. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxic assay for anticancer drug-screening. J Natl Cancer Inst 1990;13:1107-12.
33. Kern DH, Morgan CR, Hildebrand-Zanki SU. In vitro pharmacodynamics of 1-β-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum (II). Cancer Res 1988;48:117-21.
34. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 1998;41:385-90.
35. Arancia G, Leonetti C, Malorni W, et al. Different effects of sequential combinations of N-methylformamide with 5-fluorouracil on human colon carcinoma cells growing in nude mice. J Cancer Res Clin Oncol 1991;117:351-8.
36. Geran RI, Greenberg NH, Macdonald MM, Shumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 1972;3:1-88.
37. Zoli W, Ricotti L, Tesei A, Barzanti F, Amadori D. In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 2001;37:69-82.
38. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953;3:285-320.
39. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981;35:269-335.
40. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol 1979;5:85-91.
41. Kano Y, Ohnuma T, Okano T, Holland JF. Effects of vincristine in combination with methotrexate and other anti-tumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res 1988;48:351-6.
42. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1987;22:27-55.
43. Kanzawa F, Nishio K, Fukuoka K, Sunami T, Saijo N. In vitro interactions of a new derivative of spycamycin, KRN5500, and other anticancer drugs using a three-dimensional model. Cancer Chemother Pharmacol 1999;43:353-63.
44. Arango D, Wilson AJ, Shi Q, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004;9:1931-46.
45. Longley DB, Allen WL, McDermott U, et al. The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. Clin Cancer Res 2004;10:3562-71.
46. von Haefen C, Gillissen B, Hemmati PG, et al. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 2004;23:8320-32.